» Articles » PMID: 9120925

The International Continence Society "Benign Prostatic Hyperplasia" Study: International Differences in Lower Urinary Tract Symptoms and Related Bother

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 1997 Apr 1
PMID 9120925
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We investigated the international differences in the reporting of lower urinary tract symptoms and related bother in patients with symptoms suggestive of bladder outlet obstruction.

Materials And Methods: Multiple logistic regression analysis was used to evaluate international differences in the reporting of lower urinary tract symptoms and related bother in 1,271 patients from 12 countries who participated in the International Continence Society "benign prostatic hyperplasia" study.

Results: Country of origin was significantly associated with the prevalence of a large number of lower urinary tract symptoms (10 of 20), even after adjusting for potentially confounding variables, including physical and socio-demographic factors. Country of origin was also significantly associated with the reporting of bother but for a much smaller number of symptoms (2).

Conclusions: In different countries lower urinary tract symptoms may be reported to different extents. Therefore, the results of studies in particular countries may not be generally applicable to other countries. It is likely that symptom scores will conceal this variation, necessitating consideration of individual symptoms (as in the International Continence Society "benign prostatic hyperplasia" study) or the development of country specific scoring systems. An alternative would be to focus on bother, which appeared to be much less sensitive to international differences.

Citing Articles

Comparison of three questionnaire forms used in the diagnosis of lower urinary tract symptoms: A prospective study.

Guzelsoy M, Erkan A, Ozturk M, Zengin S, Coban S, Turkoglu A Prostate Int. 2022; 10(4):218-223.

PMID: 36570650 PMC: 9747591. DOI: 10.1016/j.prnil.2022.06.001.


Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labeled Study.

Honda M, Kimura Y, Teraoka S, Kawamoto B, Morizane S, Hikita K Yonago Acta Med. 2022; 65(3):231-237.

PMID: 36061573 PMC: 9419226. DOI: 10.33160/yam.2022.08.009.


Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy.

Cai T, Wang N, Liang L, Zhou Z, Zhang Y, Cui Y Int Neurourol J. 2021; 24(4):365-374.

PMID: 33401358 PMC: 7788324. DOI: 10.5213/inj.2040146.073.


Treatment of Concomitant OAB and BPH.

Moss M, Rezan T, Karaman U, Gomelsky A Curr Urol Rep. 2017; 18(1):1.

PMID: 28092069 DOI: 10.1007/s11934-017-0649-z.


Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder.

Lee S, Lee J Prostate Int. 2014; 2(2):43-9.

PMID: 25032191 PMC: 4099395. DOI: 10.12954/PI.14045.